Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers.

× No keyword cloud information.

11 in total

1. The Use of Idarucizumab for Dabigatran Reversal in Clinical Practice: A Case Series.

Authors: Pavel Goriacko; Vicken Yaghdjian; Issam Koleilat; Mark Sinnett; Harshal Shukla
Journal: P T Date: 2017-11

2. Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Authors: Timothy C Hutcherson; Nicole E Cieri-Hutcherson; Rajvi Bhatt
Journal: P T Date: 2017-11

3. Drug therapy in anticoagulation: which drug for which patient?

Authors: Carolyn M Millar; Mike A Laffan
Journal: Clin Med (Lond) Date: 2017-06 Impact factor: 2.659

Review 4. Reversal of direct oral anticoagulants: a practical approach.

Authors: Andrew W Shih; Mark A Crowther
Journal: Hematology Am Soc Hematol Educ Program Date: 2016-12-02

Review 5. [Management of hemorrhage in patients treated with direct oral anticoagulants].

Authors: O Grottke; H Lier; S Hofer
Journal: Anaesthesist Date: 2017-09 Impact factor: 1.041

Review 6. Current status of oral anticoagulant reversal strategies: a review.

Authors: Aranyak Rawal; Devarshi Ardeshna; Sheharyar Minhas; Brandon Cave; Uzoma Ibeguogu; Rami Khouzam
Journal: Ann Transl Med Date: 2019-09

7. A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer.

Authors: Gururaj Shivange; Karol Urbanek; Piotr Przanowski; Justin S A Perry; James Jones; Robert Haggart; Christina Kostka; Tejal Patki; Edward Stelow; Yuliya Petrova; Danielle Llaneza; Marty Mayo; Kodi S Ravichandran; Charles N Landen; Sanchita Bhatnagar; Jogender Tushir-Singh
Journal: Cancer Cell Date: 2018-08-13 Impact factor: 31.743

8. Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.

Authors: Stephen Norris; Steven Ramael; Ippei Ikushima; Wouter Haazen; Akiko Harada; Viktoria Moschetti; Susumu Imazu; Paul A Reilly; Benjamin Lang; Joachim Stangier; Stephan Glund
Journal: Br J Clin Pharmacol Date: 2017-04-06 Impact factor: 4.335

Review 9. Dabigatran approaching the realm of heparin-induced thrombocytopenia.

Authors: Patricia J Ho; Juan A Siordia
Journal: Blood Res Date: 2016-06-23

10. Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.

Authors: Stephan Glund; Joachim Stangier; Joanne van Ryn; Michael Schmohl; Viktoria Moschetti; Wouter Haazen; Marina De Smet; Dietmar Gansser; Stephen Norris; Benjamin Lang; Paul Reilly; Jörg Kreuzer
Journal: Clin Pharmacokinet Date: 2017-01 Impact factor: 6.447